在匈牙利的微区域之间糖尿病死亡率的不平等
Zsófia Kollányi1, Lajos Bálint2,3, Kitti Susovits4
1Faculty of Social Sciences, Eötvös Loránd University, Budapest, Hungary.
International journal of public health
|November 29, 2023
概括
匈牙利的微区域之间,糖尿病死亡率有很大差异. 缺乏杂货店和与酒精有关的高死亡率是这些差异的关键驱动因素,突出了针对性干预的必要性.
科学领域:
- 公共卫生 公共卫生
- 流行病学 流行病学
- 医疗保健服务研究 医疗服务研究
背景情况:
- 在匈牙利,糖尿病死亡率存在显著的区域差异.
- 了解这些不平等的社会经济和医疗保健相关驱动因素对于有效的公共卫生干预至关重要.
研究的目的:
- 确定导致匈牙利197个小区域糖尿病死亡率不平等的关键因素.
- 在两个不同的时期 (2009-2012年和2013-2016年) 分析这些驱动因素,以考虑社会和医疗条件的变化.
主要方法:
- 跨截面研究设计,使用来自匈牙利197个小区域的数据.
- 使用了普通最小平方 (OLS) 回归模型.
- 包括社会经济贫困和医疗保健的传统和重新概念化的措施.
主要成果:
- 居住在"服务沙漠"的居民比例较高的微区域,特别是缺乏杂货店的微区域,呈现出最高的糖尿病死亡率.
- 与酒精相关的死亡率成为糖尿病死亡率的强大和显著预测因素,其影响与食物获取问题的影响相当.
- 分析的两个时期都显示出类似的模式,表明不平等的持续驱动因素.
结论:
- 干预措施应侧重于改善服务密度低的地区的粮食供应,以减轻糖尿病死亡率.
- 加强和准酒精政策对于解决糖尿病死亡率的重要因素至关重要.
- 解决"服务沙漠"和与酒精有关的伤害对于减少糖尿病护理中的健康不平等至关重要.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
Oral Hypoglycemic Agents: Biguanides and Glitazones
209
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
209
Diabetes Mellitus: Overview and Type I Subtype
2.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K
Diabetes: Symptoms, Diagnosis, and Complications
554
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
554
Pathophysiology of Diabetes
950
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
950
Dipeptidyl Peptidase 4 Inhibitors
190
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
190


